Skip to main content
CRIS
NASDAQ Life Sciences

Curis Schedules Shareholder Vote on Reverse Stock Split to Avoid Nasdaq Delisting

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.499
Mkt Cap
$19.489M
52W Low
$0.464
52W High
$3.13
52W Position info
7.6% above low
Off High info
84% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

CRIS is trading near its 52-week low of $0.464 (7.6% above the low) on light trading volume (0.2× avg).

Summary

Curis Inc. has filed a definitive proxy statement scheduling a special meeting on June 25, 2026, for shareholders to vote on a reverse stock split, a measure aimed at increasing its share price to meet Nasdaq's listing requirements and prevent delisting.


Key Events · Corporate Governance and Compliance · CRIS

  • Special Shareholder Meeting Scheduled

    A special meeting will be held on June 25, 2026, for stockholders to vote on a reverse stock split proposal.

  • Reverse Stock Split Proposal

    The Board seeks approval for amendments to its charter to effect a reverse stock split with a ratio ranging from 1-for-5 to 1-for-25, at the Board's discretion.

  • Nasdaq Delisting Threat

    The primary reason for the reverse split is to increase the stock price to meet Nasdaq's minimum $1.00 bid price requirement, following a delisting determination letter received on April 27, 2026.

  • Financial Distress Context

    This proposal follows recent disclosures of 'going concern' doubt and significant net losses, highlighting the company's precarious financial position.


Analysis · CRIS · Life Sciences

This definitive proxy statement formalizes the company's plan to implement a reverse stock split, a critical step in its effort to regain compliance with Nasdaq's minimum bid price requirement and avoid delisting. The company previously received a delisting determination letter from Nasdaq and has disclosed substantial doubt about its ability to continue as a going concern. While a reverse split does not change the company's intrinsic value, it is a necessary defensive measure to maintain its exchange listing, which is vital for liquidity and investor confidence, especially for a company in financial distress.

At the time of this filing, CRIS was trading at $0.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.5M. The 52-week trading range was $0.46 to $3.13. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRIS - Latest Insights

CRIS
Jul 02, 2026, 8:56 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.4397
Real-time Price: $4.52 info
Change: Reverse Stock Split info
Market Cap: $8.809M info
CRIS
Jul 01, 2026, 11:22 AM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $0.4861
Real-time Price: $4.52 info
Change: Reverse Stock Split info
Market Cap: $8.809M info
CRIS
Jul 01, 2026, 8:02 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.4923
Real-time Price: $4.52 info
Change: Reverse Stock Split info
Market Cap: $8.809M info
CRIS
Jun 26, 2026, 9:43 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $0.2269
Real-time Price: $4.52 info
Change: Reverse Stock Split info
Market Cap: $8.809M info
CRIS
Jun 25, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.1985
Real-time Price: $4.52 info
Change: Reverse Stock Split info
Market Cap: $8.809M info